ArticleMovement disorders clinical practice2026
Survival after Subthalamic Deep Brain Stimulation for Parkinson's Disease: 25-Year Experience from a Single Center.
Article in Movement disorders clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere are limited data on the long-term survival of patients with Parkinson's disease (PD) undergoing subthalamic nucleus deep brain stimulation (STN-DBS).
objectivesThe aim of the study was to estimate the long-term survival and its predictors in patients who underwent STN-DBS.
methodsThe baseline demographic and clinical features of patients who underwent STN-DBS for PD at our center and had at least 5 years of follow-up were analyzed. Survival status, the date of demise, and the cause of death were obtained by telephonic interview with family members.
resultsA total of 186 patients who underwent STN-DBS between 1999 and 2018 (age at surgery: 56.7 ± 9.3 years) and were contactable in 2024 were included; 85 had died by 2024. Progressive worsening of PD, intercurrent infections, and cardiovascular diseases were the leading causes of death. The median survival after surgery was 13.1 years (interquartile range [IQR]: 8.9-17.1). Baseline postural instability and gait dysfunction subtype (hazard ratio [HR]: 2.3; 95% confidence interval [CI]:1.4-3.8, P = 0.001), higher levodopa-equivalent daily dosage (HR: 2.5; 95%CI: 1.4-4.5; P = 0.002), and higher Unified Parkinson's Disease Rating Scale Part I (UPDRS I) score in the ON state (HR: 2.8; 95% CI: 1.8-4.9; P < 0.001) were independent predictors of shorter survival, whereas higher levodopa response was an independent predictor of longer survival (HR: 0.19; 95% CI: 0.07-0.48; P = 0.001).
conclusionsSTN-DBS offers a median survival of around 13 years; predominant axial features, neurocognitive changes, poor levodopa response, and higher medication requirement at baseline portend shorter survival. These findings could influence surgical candidate selection and long-term care strategies in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.